By Colin Kellaher
Incyte unveiled positive top-line results from a pair of late-stage studies of its povorcitinib drug candidate in the chronic, inflammatory skin condition hidradenitis suppurativa.
Incyte on Monday said both Phase 3 studies met their primary endpoint at both tested doses, showing statistically significant reductions in total abscess and inflammatory nodule count.
The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to irreversible tissue destruction and scarring.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 07:21 ET (11:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。